Skip to main content
Top
Published in: Lung 1/2014

01-02-2014

Stratification of Malignant Pleural Mesothelioma Prognosis Using Recursive Partitioning Analysis

Authors: Hidekazu Suzuki, Kazuhiro Asami, Tomonori Hirashima, Norio Okamoto, Tadahiro Yamadori, Motohiro Tamiya, Naoko Morishita, Takayuki Shiroyama, Sawa Takeoka, Akio Osa, Yuichiro Azuma, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi, Ichiro Kawase

Published in: Lung | Issue 1/2014

Login to get access

Abstract

Purpose

Prognostic factors and complicated prognostic models have been proposed for malignant pleural mesothelioma (MPM). This study was designed to stratify MPM prognosis by using a simple model.

Methods

Patients diagnosed with MPM in the past 10 years (n = 122) were examined retrospectively. Data on the presence of chest pain, performance status (PS), asbestos exposure, smoking status, white blood cell count (WBC), haemoglobin (Hb) concentration, platelet count (PLT), lactate dehydronate (LD), histology, stage, and date of death or censored status were collected. After the factors were examined in the univariate analysis, recursive partitioning analysis was performed.

Results

Statistically significant factors related to survival were the type of histology, stage, PS, WBC, PLT, Hb concentration, and LD. Histology, stage, PS, and Hb concentration were used in multivariate analysis. Stage and Hb concentration showed good statistical significance, whereas PS was borderline significant. The survival analyses were stratified into five groups by PS, stage, Hb concentration, and chest pain using recursive partitioning analysis. Group A comprised patients showing the most favourable prognoses (PS 0–2 and Hb concentration >12.1 g dL−1 or PS 0–2 and Hb concentration ≤12.1 g dL−1 without pain), and group B comprised the remaining patients. The median overall survival in groups A and B was 563 days (95 % confidence interval [CI] 502–779) and 157 days (95 % CI 115–224), respectively (hazard ratio of 5.44 [3.46–8.53, P < 0.0001]).

Conclusions

The MPM patients with PS 0–2 and Hb concentration >12.1 or ≤12.1 g dL−1 without chest pain had favourable prognoses.
Literature
1.
go back to reference Kanazawa N, Ioka A, Tsukuma H, Ajiki W, Oshima A (2006) Incidence and survival of mesothelioma in Osaka, Japan. Jpn J Clin Oncol 36:254–257CrossRefPubMed Kanazawa N, Ioka A, Tsukuma H, Ajiki W, Oshima A (2006) Incidence and survival of mesothelioma in Osaka, Japan. Jpn J Clin Oncol 36:254–257CrossRefPubMed
2.
go back to reference Nojiri S, Gemba K, Aoe K, Kato K, Yamaguchi T, Sato T, Kubota K, Kishimoto T (2011) Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 41:32–39CrossRefPubMed Nojiri S, Gemba K, Aoe K, Kato K, Yamaguchi T, Sato T, Kubota K, Kishimoto T (2011) Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 41:32–39CrossRefPubMed
3.
go back to reference van der Bij S, Koffijberg H, Burgers JA, Baas P, van de Vijver MJ, de Mol BA, Moons KG (2012) Prognosis and prognostic factors of patients with mesothelioma: a population-based study. Br J Cancer 107:161–164PubMedCentralCrossRefPubMed van der Bij S, Koffijberg H, Burgers JA, Baas P, van de Vijver MJ, de Mol BA, Moons KG (2012) Prognosis and prognostic factors of patients with mesothelioma: a population-based study. Br J Cancer 107:161–164PubMedCentralCrossRefPubMed
4.
go back to reference Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113:723–731CrossRefPubMed Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113:723–731CrossRefPubMed
5.
go back to reference Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16:145–152PubMed Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16:145–152PubMed
6.
go back to reference Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644CrossRefPubMed Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644CrossRefPubMed
7.
go back to reference van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–6889CrossRefPubMed van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–6889CrossRefPubMed
8.
go back to reference Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122–1128CrossRefPubMed Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122–1128CrossRefPubMed
9.
go back to reference Torsten H, Kurt H, Achim Z (2006) Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat 15:651–674CrossRef Torsten H, Kurt H, Achim Z (2006) Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat 15:651–674CrossRef
10.
go back to reference John C, Antje H (2012) Prognostic groups by tree-based partitioning and data refinement methods. In: Handbook of statistics in clinical oncology, 3rd edn. CRC Press, Boca Raton, pp 505–528 John C, Antje H (2012) Prognostic groups by tree-based partitioning and data refinement methods. In: Handbook of statistics in clinical oncology, 3rd edn. CRC Press, Boca Raton, pp 505–528
11.
go back to reference Suzuki H, Hirashima T, Kobayashi M, Okamoto N, Matsuura Y, Tamiya M, Morishita N, Okafuji K, Shiroyama T, Morimura O, Morita S, Kawase I (2012) Prognostic factors in malignant pleural mesothelioma: a retrospective study. Intern Med 51:707–710CrossRefPubMed Suzuki H, Hirashima T, Kobayashi M, Okamoto N, Matsuura Y, Tamiya M, Morishita N, Okafuji K, Shiroyama T, Morimura O, Morita S, Kawase I (2012) Prognostic factors in malignant pleural mesothelioma: a retrospective study. Intern Med 51:707–710CrossRefPubMed
12.
go back to reference Kindler HL (2012) Robust data: the essential foundation of a revised staging system for pleural mesothelioma. J Thorac Oncol 7:1623–1624CrossRefPubMed Kindler HL (2012) Robust data: the essential foundation of a revised staging system for pleural mesothelioma. J Thorac Oncol 7:1623–1624CrossRefPubMed
13.
go back to reference Richards WG, Godleski JJ, Yeap BY, Corson JM, Chirieac LR, Zellos L, Mujoomdar A, Jaklitsch MT, Bueno R, Sugarbaker DJ (2010) Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer 116:1510–1517CrossRefPubMed Richards WG, Godleski JJ, Yeap BY, Corson JM, Chirieac LR, Zellos L, Mujoomdar A, Jaklitsch MT, Bueno R, Sugarbaker DJ (2010) Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer 116:1510–1517CrossRefPubMed
14.
go back to reference Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Pass H, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP (2012) Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 7:1631–1639CrossRefPubMed Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Pass H, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP (2012) Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 7:1631–1639CrossRefPubMed
15.
go back to reference Kao SC, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, van Zandwijk N, Clarke S (2013) Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales dust diseases board. Clin Lung Cancer 14:70–77CrossRefPubMed Kao SC, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, van Zandwijk N, Clarke S (2013) Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales dust diseases board. Clin Lung Cancer 14:70–77CrossRefPubMed
16.
go back to reference Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55:731–735PubMedCentralCrossRefPubMed Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55:731–735PubMedCentralCrossRefPubMed
17.
go back to reference Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R (2005) Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23:184–189CrossRefPubMed Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R (2005) Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23:184–189CrossRefPubMed
18.
go back to reference Mineo TC, Ambrogi V (2012) Malignant pleural mesothelioma: factors influencing the prognosis. Oncology (Williston Park) 26:1164–1175 Mineo TC, Ambrogi V (2012) Malignant pleural mesothelioma: factors influencing the prognosis. Oncology (Williston Park) 26:1164–1175
19.
go back to reference Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V (2007) Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2:957–965CrossRefPubMed Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V (2007) Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2:957–965CrossRefPubMed
20.
go back to reference Musk AW, Olsen N, Alfonso H, Reid A, Mina R, Franklin P, Sleith J, Hammond N, Threlfall T, Shilkin KB, de Klerk NH (2011) Predicting survival in malignant mesothelioma. Eur Respir J 38:1420–1424CrossRefPubMed Musk AW, Olsen N, Alfonso H, Reid A, Mina R, Franklin P, Sleith J, Hammond N, Threlfall T, Shilkin KB, de Klerk NH (2011) Predicting survival in malignant mesothelioma. Eur Respir J 38:1420–1424CrossRefPubMed
21.
go back to reference Higashiguchi M, Suzuki H, Hirashima T, Kobayashi M, Goya S, Okamoto N, Matsuura Y, Tamiya M, Morishita N, Tsumori T, Kawase I (2012) A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma. Anticancer Res 32:609–613PubMed Higashiguchi M, Suzuki H, Hirashima T, Kobayashi M, Goya S, Okamoto N, Matsuura Y, Tamiya M, Morishita N, Tsumori T, Kawase I (2012) A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma. Anticancer Res 32:609–613PubMed
Metadata
Title
Stratification of Malignant Pleural Mesothelioma Prognosis Using Recursive Partitioning Analysis
Authors
Hidekazu Suzuki
Kazuhiro Asami
Tomonori Hirashima
Norio Okamoto
Tadahiro Yamadori
Motohiro Tamiya
Naoko Morishita
Takayuki Shiroyama
Sawa Takeoka
Akio Osa
Yuichiro Azuma
Kyoichi Okishio
Tomoya Kawaguchi
Shinji Atagi
Ichiro Kawase
Publication date
01-02-2014
Publisher
Springer US
Published in
Lung / Issue 1/2014
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-013-9516-y

Other articles of this Issue 1/2014

Lung 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.